OncoImmune
is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of cancer and autoimmune diseases... Read moreOncoImmune
is a biopharmaceutical company that develops and commercializes immunotherapies for the treatment of cancer and autoimmune diseases... Read more
News
Nov 28, 2020
Pulse2.0
OncoImmune: Why Merck (MRK) Is Buying OncoImmune For $425 Million
Nov 27, 2020
Global Legal Chronicle
OncoImmune: Merck's Shares Acquisition Of OncoImmune
Nov 24, 2020
Medical Buyer
OncoImmune: Merck adds experimental COVID-19 therapy with OncoImmune deal
Nov 23, 2020
The Business Journals: Washington, D.C.
OncoImmune: Rockville biopharma to be acquired by Merck for $425M
Nov 23, 2020
BioPharma Dive
OncoImmune: Merck, expanding coronavirus work, buys a small biotech and its COVID-19 drug
Nov 23, 2020
CNBC
OncoImmune: Merck acquires OncoImmune to ramp supply of promising Covid drug
Nov 23, 2020
MarketWatch
OncoImmune: Merck to pay $425 million upfront to buy COVID-19 treatment developer OncoImmune
Sep 25, 2020
Clinical Trials Arena
OncoImmune: OncoImmune's drug lowers death risk in Phase III Covid-19 trial
Sep 25, 2020
PharmaLeaders
OncoImmune: OncoImmune's SACCOVID demonstrates significant therapeutic efficacy in Covid-19 trial
Sep 23, 2020
MarketScreener
OncoImmune: OncoImmune Launches First-in-human Clinical Trial for ONC-392 - The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy
